US Activist Hedge Fund Institutional SEC 13D 13G β October 15, 2026
Across the 47 filings, the dominant activity is passive institutional 13G disclosures (roughly two-thirds of the set), with a smaller but high-materiality cluster of contested or transformational control events. The most material developments are the PAG take-private at $212.00 cash by the Penske/Mitsui investor group (materiality 9/10, with a $383M termination fee and an Outside Date of October 15, 2027), the Reliance Global Group proxy-contest demand to remove all five directors, and the Psyence Biomedical control-level stake of 49.75% obtained via share swap. Activist and strategic-intent 13Ds are concentrated in small and micro-cap names: Third Point at Strata Critical Medical (5.8%, explicit call for strategic alternatives including a sale), Fairmount at Alaunos (capped at 19.99% with far larger convertible preferred exposure), and Ruen Hua at Gogoro (21.92% with governance ties). Insider and sponsor selling is visible at Bleichroeder/MDxHealth (17 open-market sales at $0.51-$0.67, 32% stake) and Liontrust/MaxCyte, while Saba and Drew Holdings are accumulating (Drew bought 2.75M Borr shares at $4.27-$4.93, bringing it to 13.1%). Period-over-period comparisons are largely absent in the source data because most filings are ownership snapshots rather than financial reports, so trend analysis is limited to position changes and transaction prices. Recent M&A and exit events (LogicMark $1.31 cash-out, Alaunos/Velaris merger, PAG take-private) indicate a live take-private and consolidation environment among small caps.